Exagen
Exagen, QMUL to Develop Molecular Signatures for Rheumatoid Arthritis Therapy Selection
The assays under development will segment patients according to gene expression in their synovial tissue biopsies to personalize therapy selection.
Industry experts say a receptive market and investor interest in new technologies have spurred the increase in genomics tools and molecular diagnostics IPOs.
Exagen Records Sharp Increase in Revenues for First Nine Months of 2014
NEW YORK (GenomeWeb) – Exagen Diagnostics said in a regulatory document that its revenues through the first nine months of 2014 grew almost four-fold year over year.
Biogen Idec has hired Olivier Danos as senior VP of gene therapy. Danos will report to Douglas Williams, executive VP of R&D at Biogen Idec. At Biogen Idec, he will be in charge of the gene therapy research group, which develops new technologies for gene transfer and genome engineering.
Exagen Raises $3.95M
NEW YORK (GenomeWeb) – Rheumatology and autoimmune diagnostics firm Exagen Diagnostics has raised $3.95 million, it said in a regulatory document on Monday.
Oct 30, 2013
Oct 18, 2013
Exagen Diagnostics Raises $5M
Oct 25, 2012
New York Approves Exagen Lupus Test
Oct 11, 2010
Genomic Tests Firm Exagen Buying Cypress’ Dx Biz
Jul 8, 2010
Exagen Receives CAP Accreditation
Feb 16, 2010
EndoChoice to Promote Exagen Tests
Dec 2, 2009
Pairings: Dec 2, 2009
Premium
Feb 20, 2009
People in the News: Feb 20, 2009
Feb 18, 2009